Can iron overload cause hypogonadism by depositing in the pituitary and testes?

Iron overload significantly impacts the hypothalamic-pituitary-gonadal (HPG) axis by depositing excess iron into key endocrine tissues, leading to both primary and secondary hypogonadism. This process is driven by the susceptibility of these tissues to iron-mediated oxidative damage and specialized forms of cell death.

Clinical and mechanistic evidence

The endocrine system is uniquely vulnerable to systemic iron overload, as seen in conditions like hereditary hemochromatosis and transfusion-dependent thalassemia.

• Pituitary deposition: The anterior pituitary is a primary site for iron accumulation because it lacks blood-brain barrier protection. This deposition is clinically detectable via T2* MRI, where reduced signal intensity correlates with tissue iron concentrations. Iron preferentially targets gonadotrophs, the cells responsible for secreting luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
• Testicular damage: Iron also accumulates directly in the testes. Evidence indicates that impaired iron export (due to reduced ferroportin expression) and the degradation of iron-storage proteins (ferritinophagy) increase the pool of "free" or labile iron within Leydig and germ cells.
• Hormonal disruption: The resulting HPG axis failure is often "mixed" hypogonadism. Secondary hypogonadism occurs when damaged pituitary gonadotrophs fail to produce LH and FSH, while primary hypogonadism occurs when iron accumulation in the testes directly impairs the biosynthesis of testosterone.

Cellular mechanisms of injury

The damage caused by iron is not merely structural but is driven by specific biochemical pathways:

• Oxidative and ER stress: Excess iron catalyzes the formation of reactive oxygen species (ROS) through Fenton chemistry. In the pituitary, this triggers endoplasmic reticulum (ER) stress and lipid peroxidation, leading to cellular apoptosis.
• Ferroptosis: In the testes, iron overload induces ferroptosis—a distinct, iron-dependent form of regulated cell death. This process involves the depletion of glutathione and the massive oxidation of membrane lipids, which destroys Leydig cell function and downregulates critical steroidogenic enzymes (e.g., StAR and CYP11A1) necessary for testosterone production.
• Inhibitory signaling: Iron-induced oxidative stress in the hypothalamus can also impair the pulsatile release of Gonadotropin-Releasing Hormone (GnRH), further suppressing the signaling required for normal gonadal function.

Clinical implications

The impact of iron on male reproductive health is often progressive and may become irreversible if the iron-induced tissue damage is extensive.

• Screening: Patients with high serum ferritin or known iron overload conditions should be screened for hypogonadism, even if they are asymptomatic, as endocrine dysfunction is one of the earliest complications.
• Treatment effects: While iron chelation therapy or phlebotomy can reduce systemic iron stores and potentially improve pituitary function, established damage to the gonadotrophs or Leydig cells may necessitate lifelong testosterone replacement therapy.
• Iron mobilization: Notably, starting testosterone replacement can suppress hepcidin (the master iron regulator), which may mobilize stored iron and theoretically influence iron dynamics in the body.

Bottom line

Iron overload disrupts the HPG axis by depositing iron in the anterior pituitary and testes, where it triggers oxidative stress, apoptosis, and ferroptosis. This results in impaired production of LH, FSH, and testosterone, leading to a combination of primary and secondary hypogonadism that may be irreversible if not addressed early.